This open-label , randomized study evaluated efficacy and safety of artemether-lumefantrine ( AL ) and dihydroartemisinin-piperaquine ( DP ) in treatment of uncomplicated falciparum malaria in children below five years of age , to build evidence on use of AL as first-line treatment and DP as second-line treatment in Kenya .